Evolving Oral PrEP Guidance for Cis Women: What do we know, and what will it take?

Wednesday23September

14:00 - 15:30 GMT

Virtual

Scientific consensus is evolving, but PrEP clinical equity remains unachieved. Recent data has challenged the “conventional wisdom” surrounding vaginal PrEP tissue concentrations, proving oral PrEP (TDF/FTC, TAF/FTC) is significantly more forgiving than historic messaging for cis women suggested. This has implications for what we understand as “time to protection” as well as “on-demand” PrEP, and may impact trans and non-binary people as well.

What will it take to update the discordant guidelines for women? Can better, more accurate alignment advance equity for cis women, trans folks and non-binary people?

Speakers (in formation):

Heather-Marie Anne Schmidt, UNAIDS
Simon Collins, HIV i-Base
Dr. Jenell Stewart, University of Minnesota
Dr. Raphael Landovitz, University of California Los Angeles

Featured Resources

Document

Nigeria National HIV Prevention Plan 2026–2030

This plan, developed by Nigeria’s Federal Ministry of Health and Social Welfare and National Agency for the Control of AIDS, provides a roadmap for reversing the HIV epidemic in Nigeria.

Document

Ghana National HIV Prevention Roadmap, 2026-2028

This National HIV Prevention Roadmap 2026-2028 outlines Ghana’s HIV and AIDS prevention measures which are based on the five core prevention pillars -Adolescent Girls and Young Women, Adolescent Boys and Young Men, Vulnerable Populations, Condoms, and Anti-Retroviral based Prevention.

Document

Mozambique Guidelines for Combined Biomedical Prevention of HIV, STIs, and Viral Hepatitis, 2025

These clinical guidelines, developed by Mozambique’s Ministry of Health in 2025, can be used to support delivery of both PrEP and PEP, including newer, long-acting options such as injectable lenacapavir (LEN), cabotegravir (CAB), and the dapivirine vaginal ring (DVR).

Document

Lesotho Addendum to HIV Prevention, Treatment, and Care Guidelines, 2026

These clinical guidelines, developed by Lesotho’s Ministry of Health in 2026, can be used to support delivery of both PrEP and PEP, including newer, long-acting options such as injectable lenacapavir (LEN), cabotegravir (CAB), and the dapivirine vaginal ring (DVR).

Document

Eswatini Pre-Exposure Prophylaxis Implementation Guidelines, 2025

These implementation guidelines, developed by Eswatini’s Ministry of Health in 2025, can be used to support delivery of PrEP, including newer, long-acting options such as injectable lenacapavir (LEN), cabotegravir (CAB), and the dapivirine vaginal ring (DVR).

Document

Kenya Integrated Guidelines for Prevention, Treatment and Management of HIV, Sexually Transmitted Infections and Viral Hepatitis, 2026

These clinical guidelines, developed by Kenya’s Ministry of Health in 2026, can be used to support delivery of both PrEP and PEP, including newer, long-acting options such as injectable lenacapavir (LEN), cabotegravir (CAB), and the dapivirine vaginal ring (DVR).

External Link

Global PrEP Tracker

Last update: April 2026 Visit data.prepwatch.org for a dynamic map-based tool to explore trends in PrEP use globally, including by country, product, and time period. Comprehensive datasets are available to download by clicking “download data” in the upper righthand corner. For any questions, contact [email protected]. Introduction to the Global PrEP Tracker

External Link

PrEP Drug Interaction Checker

This website, developed and maintained by the University of Liverpool, provides clear, trustworthy, and up-to-date information about how different PrEP options, including oral PrEP, cabotegravir, lenacapavir, and the dapivirine vaginal ring, can interact with other drugs.

Document

Zambia PrEP Training Materials for Clinicians and Community Mobilisers

These materials, developed by Zambia’s Ministry of Health, can be used to train clinicians and mobilisers in delivery of PrEP methods, including injectable lenacapavir (LEN), cabotegravir (CAB), the dapivirine vaginal ring (DVR), the Dual Prevention Pill (DPP), and oral PrEP.

Document

Zambia Guidelines for Pre and Post-Exposure Prophylaxis for HIV Infection, 2025

These clinical guidelines, developed by Zambia’s Ministry of Health in 2025, can be used to support delivery of both PrEP and PEP, including newer, long-acting options such as injectable lenacapavir (LEN), cabotegravir (CAB), and the dapivirine vaginal ring (DVR), as well as the Dual Prevention Pill and oral PrEP.